光正眼科2025年首季归母净利润实现扭亏 增长幅度达103%

Core Insights - The company reported a revenue of 208 million yuan and a net profit attributable to shareholders of 573,800 yuan for Q1 2025, marking a turnaround with a 103.06% improvement compared to the same period last year [1] - The company is focusing on high-end cataract and refractive surgery, transitioning from basic cataract surgeries to advanced refractive cataract surgeries to meet the increasing quality demands of middle-aged and elderly patients [1][2] - The refractive and cataract projects remain the core business, generating revenues of 258 million yuan and 288 million yuan respectively, accounting for 61.15% of total revenue, with gross margins of 43.86% and 49.87% [1] Business Strategy - The company is deepening its integrated development strategy in medical education, research, and services, collaborating with Fudan University and Jiangnan University to enhance research capabilities and innovation in eye health [2] - The company aims to implement a core strategy focused on "eye care medical business" and "smart hospital construction," emphasizing the integration of AI in services and management [2] - Future growth is expected to rely on technological upgrades, digital innovation, and resource integration to overcome profitability challenges and achieve high-quality growth in a competitive market [2]